Sun Pharma Q1 profit rises 27% as India formulations sales grow 16%

Sun Pharma posted Q1 net profit of ₹2,895 crore on revenue of ₹15,300 crore. India formulations sales rose 16% to ₹5,475 crore, lifting domestic market share to 8.5%, while US formulations revenue declined 9.7%.

— Source publishedFri, 31 Jul, 2026, 15:51 IST·First seen Fri, 31 Jul, 2026, 15:54 IST·Source Outlook Business

What happened

Sun Pharmaceutical Industries · Sun Pharma reported 27% YoY quarterly profit growth, powered by 16% growth in India formulations sales. The company launched

Key facts

  • Net profit: ₹2,895 crore, up 27% YoY
  • Revenue: ₹15,300 crore, up 10.5% YoY
  • India formulations sales: ₹5,475 crore, up 16% YoY
  • India formulations share of revenue: 36.1%
  • India market share: 8.5%, versus 8.2% a year earlier
  • US formulations sales: $427 million, down 9.7% YoY
  • Innovative medicines sales: $351 million, up 12.8% YoY
  • EBITDA: ₹4,418 crore; margin: 28.9%
  • R&D spending: ₹826 crore, or 5.4% of sales
  • Five domestic product launches

Why this matters

Sun Pharma’s expanding domestic scale strengthens its case for India-focused bolt-ons and partnerships, while US weakness may warrant portfolio-enhancing deals in differentiated products.

What to watch

  • Whether India formulations growth remains above the domestic pharmaceutical market growth rate in the next two quarters.
  • Movement in domestic market share beyond 8.5%, especially in chronic therapies and branded generics.
  • US formulations revenue trend, generic price erosion, launch contribution and specialty-product sales.
  • Gross-margin and EBITDA-margin progression as India becomes a larger share of the sales mix.
  • Any FDA inspection, warning-letter, manufacturing or supply-chain developments affecting US product availability.
  • Management commentary on US recovery timing, R&D spending and capital-allocation plans.
  • Increase promotional, distribution and field-force investment in India to consolidate share gains in chronic and specialty therapies.
  • Prioritize higher-margin domestic brands and launch cadence while selectively defending US products with sustainable economics.
  • Use strong cash generation for specialty pipeline investment, manufacturing compliance upgrades, bolt-on acquisitions or shareholder returns.
  • Guide investors toward India-market momentum and margins while providing clearer disclosure on US pricing, launches and specialty-product trends.